BoxInterferences@uspto.gov

Tel: 571-272-9797 Filed: 19 August 2015

## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOGEN MA INC. Junior Party Patent 8,399,514 B2,

v.

FORWARD PHARMA A/S Senior Party Application 11/576,871.

Patent Interference No. 106,023 (McK) Technology Center 1600

Before: FRED E. McKELVEY, SALLY GARDNER LANE, and DEBORAH KATZ, *Administrative Patent Judges*.

FRED E. McKELVEY, Administrative Patent Judge.

## **DECISION ON FORWARD PHARMA MOTION 2**

37 C.F.R. § 41.125(a)

- 1 Forward Pharma Motion 2 (Paper 163) seeks entry of an order vacating
- 2 benefit for the purpose of priority (i.e., an earlier constructive reduction to practice)



Paper 178

1	awarded to B	iogen when the	he interference	was declared	l (Paper 1	l, page 6) a	is to
---	--------------	----------------	-----------------	--------------	------------	--------------	-------

- 2 Biogen Provisional Application 60/888,921, filed 8 February 2007 (Ex. 2006A).
- The basis for the motion is that Biogen failed to amend its U.S. Application
- 4 12/526,296, filed 13 January 2011 (**Ex. 2004A**) to contain a specific reference to
- 5 the Biogen Provisional application.
- Without an amendment, Biogen is not entitled to an earlier constructive
- 7 reduction to practice based on its Provisional Application.
- 8 Biogen attempted to amend its U.S. Application 12/526,296. Biogen
- 9 Motion 5 (Paper 94).
- Biogen Motion 5 has been denied. Paper 177.
- Our decision denying Biogen Motion 5 resolves the same issue raised in
- 12 Forward Pharma Motion 2.
- Because our decision on Biogen Motion 5 grants Forward Pharma the relief
- 14 it seeks in Forward Pharma Motion 2, and Biogen had a full and fair opportunity to
- address the relief sought by Forward Pharma Motion 2 in presenting Biogen
- Motion 5, the issue raised in Forward Pharma Motion 2 has become moot.
- ORDERED, for the reasons given above, Forward Pharma Motion 2 is
- 18 dismissed as moot without prejudice to being renewed should future circumstances
- 19 dictate a need to decide Forward Pharma Motion 2.



1	cc (via-email):
2	
3	Counsel for Biogen MA Inc.:
4	
5	Michele C. Bosch, Esq.
6	Barbara C. McCurdy, Esq.
7	FINNEGAN, HENDERSON, FARABOW
8	GARRETT & DUNNER L.L.P.
9	michele.bosch@finnegan.com
10	barbara.mccurdy@finnegan.com
11	
12	Counsel for Forward Pharma A/S:
13	
14	Anthony M. Zupcic, Esq.
15	Daniel S. Glueck, Esq.
16	FITZPATRICK, CELLA, HARPER & SCINTO
17	azupcic@fchs.com
18	dglueck@fchs.com

